三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
Lepodisiran疗效优异,单次给药后Lp(a)水平最高降低超90%
Lepodisiran疗效优异,单次给药后Lp(a)水平最高降低超90%
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:109KB
图片尺寸:1736*828
同报告图片
/
4
PHxiZWdpbl9vZl9ib3h8Pnwg6I2v54mpICAgICAgICAgfCBMZXBvZGlzaXJhbiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18Cnwg5Li05bqK6K+V6aqMICAgICB8IEFMUEFDQe+8iE5DVDA1NTY1NzQy77yJICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDlhaXnu4TkurrnvqQgICAgIHwgTHAoYSniiaUxNzUgbm1vbCAvIEwgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg57uZ6I2v5pa55byPICAgICB8IOavjzE4MOWkqeS4gOasoeearuS4i+azqOWwhOe7meiNr++8jOWFsee7meiNrzLmrKEgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDliIbnu4QgICAgICAgICB8IDE2IC0gMTZtZyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgOTYgLSA5Nm1nICAgfCA0MDBtZyAtIOWuieaFsOWJgiB8Cnwg5a6J5oWw5YmC5qCh5q2j5ZCO56ysNjDlpKnoh7MxODDlpKnmnJ/pl7TlhoXlubPlnYdMcChhKeawtOW5s+i+g+Wfuue6v+mZjeW5hSB8IC00MC44JSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgLTc1LjIlICAgICAgfCAtOTMuOSUgICAgICAgIHwKfCDlronmhbDliYLmoKHmraPlkI7nrKw2MOWkqUxwKGEp5rC05bmz6L6D5Z+657q/6ZmN5bmFIHwgLTQ3LjQlICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAtODAuOSUgICAgICB8IC05NS41JSAgICAgICAgfAoK5pWw5o2u5p2l5rqQ77yaTkVKTe+8jOS4nOaWueivgeWIuOeglOeptuaJgDx8ZW5kX29mX2JveHw+
所属报告:
【东方证券】京新药业(002020)-京新药业深度报告:创新破局,再攀高峰-251121(23页).pdf
打包全文图表
相关数据
Lepodisiran针对目标Lp(a)水平从基线的下降水
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
收藏
行业数据
2025-11-20
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
小核酸药物疗效优异,小分子药物疗效相当且可及性占优。从临床数据看,siRNA 药物Lepodisiran 在 II 期临床试验中,最高剂量组在给药 1 次后 Lp(a)降幅超过 90%,小分子药物莫伐倍林给药 12周 Lp(a)降幅最高达 86%,与 siRNA大致可比,但小分子药物价格通常显著低于小核酸药物,且可及性占优,更适用于拒绝注射的患者人群。
行业数据
原图定位
当前图表所属:
【东方证券】京新药业(002020)-京新药业深度报告:创新破局,再攀高峰-251121(23页).pdf
财务报表预测与比率分析
GABAAR的α1亚型主要介导镇静催眠作用
失眠症治疗用药首选短/中效BZRA或Dora
卡利拉嗪仿制药另有3家处于临床III期阶段
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》